Nanomedical Diagnostics is organized around development of a breakthrough electrical assay based on proprietary Field Effect Biosensing (FEB) technology that provides real-time label-free kinetic binding and affinity data. Unique graphene biosensors at the heart of the assay deliver highly-sensitive kinetic characterization of small molecules ?1 Da in complex media such as DMSO, using unprecedentedly small amounts of sample, making the platform a novel orthogonal technique for drug discovery hit validation and lead optimization.
